Core Viewpoint - The integration of traditional Chinese medicine (TCM) with modern technology, particularly AI, is enhancing the diagnostic capabilities of healthcare professionals and improving patient trust in medical advice. Group 1: Development of TCM and Training - The Chinese government is actively promoting the development of TCM to ensure the safety of the healthcare system, with "Western learning Chinese" training becoming a key pathway for Western doctors to gain prescription rights for TCM [1] - Despite obtaining certificates, many Western doctors still lack confidence in prescribing TCM, highlighting a gap in practical application and patient trust [1] Group 2: Role of AI in TCM - AI tools are transforming traditional TCM practices by converting subjective assessments into objective data, thus lowering the barriers to learning and practical application [2] - For instance, devices like pulse and tongue diagnostic instruments provide visual data that help both doctors and patients understand TCM diagnostics better [2] Group 3: Enhancing Patient Trust - AI-generated diagnostic results facilitate better communication between doctors and patients, making the rationale behind diagnoses clearer and more convincing [4] - Standardized AI-generated reports allow for easy comparison of patient conditions over time, reinforcing patient trust as they see tangible improvements in their health [5] Group 4: AI as a Support Tool - AI is positioned as a supportive tool for doctors rather than a replacement, providing objective data that aids in accurate diagnosis and enhances communication with patients [7]

Group 1 - The core point of the news is that E Fund Management Co., Ltd. has reduced its stake in Tiger Med (03347.HK) by selling 161,500 shares at an average price of HKD 47.6128 per share, amounting to approximately HKD 7.6895 million [1][2] - After the reduction, E Fund's total shareholding in Tiger Med is now 9,762,400 shares, which represents a decrease in ownership percentage from 8.06% to 7.93% [1][2]

Core Viewpoint - The company is planning to revise its internal regulations and amend its articles of association to enhance corporate governance and compliance with legal requirements [2][26][29]. Group 1: Company Governance Changes - The company will no longer have a supervisory board, with its functions being transferred to the audit committee of the board of directors [26][29]. - Amendments to the articles of association and internal regulations are aimed at improving operational standards and governance [2][26][29]. Group 2: Shareholder Meeting Details - The company will hold its first extraordinary general meeting of 2025 on October 16, 2025, with both on-site and online voting options available [6][10][41]. - The record date for shareholders to attend the meeting is set for October 10, 2025 [8][10]. - Shareholders can register for the meeting through various methods, including in-person and electronic means [11][13][14]. Group 3: Voting Procedures - Voting will be conducted through the Shenzhen Stock Exchange trading system and an internet voting platform, with specific time slots designated for each [18][20]. - The voting process will require shareholders to choose between on-site and online voting, with only one method allowed per shareholder [7][10][20]. Group 4: Internal Regulation Revisions - The company has proposed revisions to several internal regulations, including rules for shareholder meetings, board meetings, and independent director systems, all of which have been approved by the board [29][30][41]. - The revised internal regulations will be submitted for approval at the upcoming extraordinary general meeting [2][41].

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002622 证券简称：皓宸医疗 公告编号：2025-024 皓宸医疗科技股份有限公司 关于修订《公司章程》及公司部分内部制度的公告 本公司董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 ■ （一）将"股东大会"调整为"股东会"； （二）删除监事会、监事相关规定，由董事会审计委员会行使《公司法》规定的监事会职权； （三）新增"控股股东和实际控制人"章节； （四）新增"独立董事"章节； （五）新增"董事会专门委员会"章节； （六）将股东会股东提案权所要求的持股比例由3%降至1%。 一、关于《公司章程》修订情况 根据《中华人民共和国公司法》（以下简称"《公司法》"）《上市公司章程指引》《关于新〈公司法〉 配套制度规则实施相关过渡期安排》等法律法规及规范性文件的规定，结合公司实际情况，公司拟不再 设置监事会，监事会的职权由董事会审计委员会行使，同时，公司《监事会议事规则》相应废止，公司 各项规章制度中涉及监事会、监事的规定不再适用。 本次事项尚需提交公司股东大会审议，同时提请股东大会授权公司经营管理层办理工商变更登 ...

医渡科技(02158)发布公告，于2025年9月29日斥资192.71万港元回购33.5万股股份。 ...

Core Viewpoint - The article emphasizes the significance of hard technology innovation as a core driver for reshaping competitive landscapes, leading industrial transitions, and addressing critical challenges in key sectors such as semiconductors, high-end equipment, and new energy [2]. Group 1: Evaluation Process - The evaluation process for the "Hard Technology Innovators" selection took three months, attracting over a hundred early-stage companies through active applications and recommendations from investment institutions [3]. - The assessment was based on three dimensions: technological and product achievements, commercial value and potential, and the influence of founding teams, utilizing a composite review model [3]. - A total of 44 companies were selected for the "2025 Worthy of Attention Hard Technology Innovators" list, with notable companies advancing to the final showcase event [3]. Group 2: Awarded Companies Overview - Among the awarded companies, 25 are in the smart manufacturing sector, focusing on sub-sectors like new energy batteries, new materials, semiconductors, and advanced equipment [5]. - The average establishment age of the awarded companies is three years, with 52% founded within one to three years [5]. - The top three regions for awarded companies are Beijing, Zhejiang, and Jiangsu, with a concentration of talent and entrepreneurial activity in these areas [5]. Group 3: Team Background - 24 awarded companies have core teams with overseas study backgrounds, and over 90% of founders hold master's degrees or higher, with nearly 70% possessing doctoral degrees [6]. - Notable educational institutions represented among founders include Tsinghua University, Fudan University, and Peking University [6]. Group 4: Financing Situation - 86% of awarded companies have historical financing records, indicating a trend towards attracting more early-stage and industrial capital as technology matures [7].

Core Viewpoint - The announcement details the resignation of Ms. Zheng Yuan from her roles as company secretary, authorized representative, and legal process agent, effective September 29, 2025, and the appointment of Mr. Huang Wenyau to fill these positions on the same date [1] Group 1 - Ms. Zheng Yuan has resigned from her positions within the company [1] - Mr. Huang Wenyau has been appointed to succeed Ms. Zheng Yuan [1] - Both changes will take effect on September 29, 2025 [1]

2025年9月16日，山东步长制药股份有限公司第五届董事会第三十二次会议通过议案，其控股子公司上 海合璞医疗科技有限公司拟共投资490万元，分别与济南恒德科技、上海裹鼎科技设立山东合璞锐诚医 疗科技有限公司、湖北合璞医疗科技有限公司，上海合璞均持股70%。近日，两家新公司完成工商登记 注册手续。山东合璞锐诚医疗科技注册资本400万元，9月24日成立；湖北合璞医疗科技注册资本300万 元，9月26日成立。相关信息已在上海证券交易所网站披露。 ...

Core Insights - The 6th China Liaoning International Investment and Trade Fair (Liaoning Fair) was held from September 25 to 28, 2023, in Shenyang, serving as a significant platform for expanding Liaoning's international cooperation and trade [3][4] - The fair attracted over 60 countries' officials, business leaders, and representatives from Fortune 500 companies, highlighting its importance in fostering global economic ties [4] Group 1: Investment and Trade Opportunities - The fair showcased various products, including an AI-assisted pathology image analysis system, indicating a focus on technological advancements in healthcare [3] - Japanese enterprises have consistently participated in the fair, signing cooperation agreements with Chinese food companies, demonstrating effective international collaboration [3] - The presence of South Korean companies, such as the automotive filter manufacturer, reflects the fair's role in facilitating business expansion and partnerships in the region [3] Group 2: Economic Growth and Foreign Investment - Liaoning's geographical advantages, including its location in the Northeast Asia economic circle and its role in the Belt and Road Initiative, enhance its appeal for foreign investment [3] - In the first half of the year, Liaoning attracted $2.87 billion in foreign direct investment, marking a 126.3% year-on-year increase [5] - The province's total import and export value reached 501.94 billion yuan in the first eight months, with exports hitting a record high of 267.67 billion yuan, reflecting robust economic performance [5]

Core Insights - The MedBench platform has released its latest evaluation results for 2025, highlighting the "Zhuomuniao Medical Model" from Zhongkang Technology, which ranked 2nd overall and 1st in medical language understanding, showcasing its significant advantages in integrating natural language processing with medical expertise [1] Group 1: Model Performance - The "Zhuomuniao Medical Model" is built on nearly two decades of data accumulation and industry insights from Zhongkang Technology, utilizing a high-quality training resource that includes over one million medical documents, guidelines, textbooks, and drug instructions, as well as tens of millions of de-identified clinical data, disease records, and unstructured medical records [1] - The model has a parameter count of 70 billion, and its performance is enhanced through large-scale pre-training and multi-stage instruction fine-tuning, along with advanced techniques such as data cleaning, deduplication, and augmentation [1] Group 2: Application and Impact - The "Zhuomuniao Medical Model" serves as an intelligent engine that spans the entire health service chain, supporting the "Healthcare Full-Scenario Intelligent Body" launched by Zhongkang Technology in March 2025 [1] - This intelligent body is developed using the Tiangong No. 1 and Zhuomuniao medical platforms, integrating high-quality industry data, professional knowledge, and leading model distillation technology to create intelligent solutions for various scenarios including commercial, medical, pharmacy, health management, and research [1] - These intelligent bodies are designed to achieve a business closed-loop characterized by "intelligent decision-making, agile action, and controllable results," thereby enhancing efficiency and service quality in the healthcare industry [1]